PITT researcher honored at ASCO's Annual Meeting for new approach to lung cancer
...n additional seven patients. The dose of 400 mg of vorinostat daily for two weeks was well-tolerated by most of the patients in the study and is the recommended dose for a subsequent study to further determine the efficacy of the drug. "A larger clinical trial for patients with advanced non-small cell lung canc......Minn., report that a novel application of the drug vorinostat shows activity in patients with recurrent glioblas...oma multiforme patients," Dr. Galanis says. "Using vorinostat to treat glioblastoma multiforme patients who have relapsed following surgery, radiation and chemoth...